Advertisement

 

 

α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus.

α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus.
Author Information (click to view)

Li Q, Wei D, Feng F, Wang XL, Li C, Chen ZN, Bian H,


Li Q, Wei D, Feng F, Wang XL, Li C, Chen ZN, Bian H, (click to view)

Li Q, Wei D, Feng F, Wang XL, Li C, Chen ZN, Bian H,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of cancer research and clinical oncology 2017 07 07() doi 10.1007/s00432-017-2470-y
Abstract
PURPOSE
Newcastle disease virus (NDV) has been applied to oncolytic virotherapy for decades due to its naturally oncolytic property. In spite of the substantiation of the sialic acid receptors of NDV on host cells, knowledge of preference of sialic acid linkage in viral attachment and oncolytic effect is lacking and imperative to be elucidated.

METHODS
Surface plasmon resonance analysis and competitive inhibition with sialylated glycan receptor analogues were used to determine the affinity and the preference of sialic acid receptor. Treatments of sialyltransferase inhibitors and linkage-specific sialidases and transfection with sialyltransferase expression vector were performed to regulate sialic acids levels.

RESULTS
We demonstrated that sialic acid was essential for NDV binding and infection of tumor cells. α2,6-linked sialic acid served as a high-affinity receptor for NDV and the ST6Gal I sialyltransferase that synthesizes α2-6 linkage of sialylated N-linked glycans in CHO-K1 cells promoted NDV binding and cytopathic effect. More importantly, an enhanced antitumor effect of NDV on aggressive SW620 colorectal carcinoma cells with high-level of cell surface α2,6-sialylation, but not SW480 cells with relative low-level of α2,6-sialylation, was observed both in vitro and in vivo.

CONCLUSIONS
The study provides evidence of optimized therapeutic strategy in oncolytic virotherapy via partly defining α2,6-sialylated receptor as a "cellular marker" for NDV.

Submit a Comment

Your email address will not be published. Required fields are marked *

14 + 7 =

[ HIDE/SHOW ]